Aptose to Announce Q1 2024 Financials and Clinical Strategy Update on May 14, 2024
May 06, 2024 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a company focused on precision oncology, will release its financial results for the first quarter ending March 31, 2024, on Tuesday, May 14, 2024, post-market close, along with a corporate update. Rafael Bejar, MD, PhD, the Chief Medical Officer of the Company, will present slides and discuss the clinical development strategy for the Company’s lead candidate, tuspetinib (TUS), in combination with venetoclax (VEN) and hypomethylating agents (HMA) for newly diagnosed acute myeloid leukemia (AML) patients.
The conference call and webcast are scheduled for Tuesday, May 14, 2024, at 5:00 PM ET. The event will include slides and can be accessed via a provided webcast link. Analysts who wish to participate in the Q&A session must pre-register using a specific link to obtain dial-in information and a unique PIN. Additionally, participants can utilize a "Call Me" feature for automatic dial-out.
The webcast will be available through a link on the Investor Relations section of Aptose's website, and a replay will be accessible for 30 days following the event. The press release, financial statements, and management's discussion and analysis for the quarter ended March 31, 2024, will be available on SEDAR and EDGAR platforms.
Aptose Biosciences is dedicated to developing targeted therapies for cancer, focusing primarily on hematological cancers. The company’s product pipeline includes highly differentiated small molecule therapeutics, designed to work effectively as standalone treatments or in combination with other anti-cancer therapies, without overlapping toxicities.
Among its clinical-stage developments are two oral kinase inhibitors for hematologic malignancies. Tuspetinib has shown promise both as a monotherapy and in combination therapy for patients with relapsed or refractory AML. It is currently being developed as a frontline treatment in a triplet combination therapy for newly diagnosed AML patients. The second candidate, luxeptinib (CG-806), is an oral dual kinase inhibitor targeting both lymphoid and myeloid malignancies. It is in Phase 1 a/b clinical trials for patients with relapsed or refractory hematologic cancers.
Aptose’s commitment lies in addressing unmet needs in oncology through precision medicines that enhance treatment efficacy and patient outcomes. Further details about the company’s research, pipeline, and ongoing clinical trials can be found on its official website.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
